ライフサイエンスコーパス: neuron-specific enolase

1 cidic protein) or neurons (synaptophysin and neuron-specific enolase).

2 duced increases in serum S100beta, GFAP, and neuron specific enolase.

3 ation of mitotic activity, and production of neuron-specific enolase.

4 ls were fixed and immunostained for LHRH and neuron-specific enolase.

5 tic peptide; and the marker of brain injury: neuron-specific enolase.

6 100B, brain-derived neurotrophic factor, and neuron-specific enolase.

7 , somatosensory-evoked potentials, and serum neuron-specific enolase.

8 for the determination of microRNA levels and neuron-specific enolase.

9 fibrovascular tissue that did not stain for neuron-specific enolase.

10 ed by a lack of change in MCAv, S100beta and neuron-specific enolase.

11 tin (64 of 66, 97%), desmin (70 of 78, 90%), neuron-specific enolase (60 of 74, 81%), and the EWS-WT1

12 duced expression of neuronal markers such as neuron specific enolase and beta-III tubulin.

13 cancer had a higher level of tumor markers (neuron-specific enolase and cytokeratin fragment 21-1).

14 concentrations peaked earliest, followed by neuron-specific enolase and finally myelin basic protein

15 uced neural morphology and markers including neuron-specific enolase and neurofilament protein.

16 Finally we identified two TMs (neuron-specific enolase and pro-gastrin-releasing peptid

17 Neuron-specific enolase and S-100 levels increased in th

18 Serum neuron-specific enolase and S100b concentrations were in

19 eviously characterized biomarkers, including neuron-specific enolase and S100B protein.

20 al morphology, expressed the neuronal marker neuron specific enolase, and were incorporated into the

21 rker profiles (progastrin-releasing peptide, neuron-specific enolase, and chromogranin-A) were analyz

22 factor-alpha, interleukin-6, complement C5a, neuron-specific enolase, and glial fibrillary acidic pro

23 Enrollment leptin, neuron-specific enolase, and intracellular cell adhesion

24 The baseline levels of chromogranin A, neuron-specific enolase, and multiple soluble angiogenic

25 Preliminary data show that serum S100b, neuron-specific enolase, and myelin basic protein may ai

26 anin A and positive for bombesin, serotonin, neuron-specific enolase, and the c-met protooncogene (a

27 serum biomarkers (matrix metallopeptidase-9, neuron-specific enolase, and vascular cellular adhesion

28 previously reported biomarkers of acute IS (neuron-specific enolase: area under the curve=0.69; inte

29 y can potentially measure injury to neurons (neuron-specific enolase), astrocytes (S100b), and axons

30 sma biomarkers (C5a, interleukin [IL] 6, and neuron-specific enolase at baseline; IL-8, tau, and ubiq

31 Additionally, S100 protein, neuron-specific enolase, beta-amyloid protein, tau prote

32 As compared to neuron-specific enolase, circulating microRNAs are modes

33 al tau, S-100 calcium-binding protein B, and neuron-specific enolase concentrations in plasma and ser

34 Serum S100 beta (S100B) and neuron-specific enolase concentrations rise after brain

35 acy, defined as the geometric area under the neuron-specific enolase curve from 24 to 72 hours after

36 ignificant differences in the area under the neuron-specific enolase curve, or a composite end point

37 Confounders of neuron-specific enolase elevation should be actively con

38 Performance Category 1-2 had confounders for neuron-specific enolase elevation.

39 ion (STAT) pathway, under the control of the neuron-specific enolase enhancer/promoter.

40 it to target cre to the 3' end of the mouse neuron-specific enolase (Eno2) gene carried on a 250-kb

41 , MUC2, MUC5AC, synaptophysin, chromogranin, neuron specific enolase, epidermal growth factor recepto

42 differences were absent for DAB1,GAD(65) and neuron-specific-enolase expression implying that RELN an

43 tio, 5.58; 95% CI, 2.56-12.16), and elevated neuron-specific enolase (false-positive rate, 0.12; 95%

44 rkers [ie, age, lactate dehydrogenase (LDH), neuron-specific enolase, ferritin, and MYCN gene amplifi

45 icant changes were detected in the levels of neuron-specific enolase from preseason values (median, 6

46 The 47.2 kDa lung cancer tumor marker neuron-specific enolase gamma (NSEgamma) was quantified

47 also measured fasting serum chromogranin A, neuron-specific enolase, gastrin, glucagon, vasoactive i

48 biomarkers (S100 calcium-binding protein B, neuron-specific enolase, glial fibrillary acidic protein

49 % vs 11%; 23 vs 4%, respectively), and serum neuron specific enolase greater than 33 ng/mL (23% vs 8%

50 corneal reflexes, presence of myoclonus, and neuron-specific enolase greater than 75 microg/L; accura

51 All three patients with neuron-specific enolase greater than 90 mug/L and Cerebr

52 d case reviews of good outcome patients with neuron-specific enolase greater than 90 mug/L and poor o

53 urden, plasma chromogranin A (>/=600 mug/L), neuron-specific enolase (>/=25 mug/L), and classic gradi

54 Using best specificity, serum S100b and neuron-specific enolase had optimal positive and negativ

55 em reflexes in normothermia (p = 0.013), and neuron-specific enolase higher than 33 mug/L (p = 0.029)

56 l and morphology were quantified by studying neuron-specific enolase-immunostained cells at various t

57 ithout any change in messenger RNA levels of neuron-specific enolase in BA 9.

58 .e., the epitope) or a target protein (i.e., neuron specific enolase) in buffer.

59 tly reduced, independently and as a ratio to neuron-specific enolase, in both prefrontal cortex and h

60 Neuron-specific enolase is an easily available, observer

61 , somatosensory-evoked potentials, and serum neuron-specific enolase, is recommended; however, no stu

62 iate filaments, labeling Muller cells) or to neuron-specific enolase (labeling retinal neurons).

63 emizygotes for the transgenes SYN-LEPR-B and neuron-specific enolase-LEPR B (NSE-LEPR-B).

64 than 90 mug/L and poor outcome patients with neuron-specific enolase less than or equal to 17 mug/L (

65 The majority of 14 patients with neuron-specific enolase less than or equal to 17 mug/L w

66 The median neuron-specific enolase level at 48 hours was also simil

67 At 48 hours, the median neuron-specific enolase level was 17 mug per liter in th

68 e score), the tumor burden, and the baseline neuron-specific enolase level.

69 Exenatide did not reduce neuron-specific enolase levels and did not significantly

70 Secondary outcomes included neuron-specific enolase levels at 48 hours, death from a

71 Secondary outcomes were neuron-specific enolase levels at 48 hours, death from a

72 er S100B levels at all time points and lower neuron-specific enolase levels on days 1 and 3 compared

73 s is not associated with neuronal loss since neuron-specific enolase levels were comparable between t

74 fluid biomarkers, such as protein 14-3-3 and neuron-specific enolase, may be useful prognostic indica

75 The level of neuron-specific enolase messenger RNA as a neuronal mark

76 Reelin, GAD(65), GAD(67), DAB1, and neuron-specific-enolase messenger RNAs (mRNAs) and respe

77 RNA expression but not that corresponding to neuron-specific enolase mRNA.

78 r pyramidal in shape, and immunoreactive for neuron-specific enolase, mu opioid receptors, and galani

79 des several neuroendocrine-associated genes (neuron-specific enolase, neurogranin), suggesting that E

80 markers of mature granule neurons including neuron specific enolase, neuronal nuclei, and the calciu

81 illary acidic protein, CD11b), and neuronal (neuron-specific enolase, neuronal nitric oxide synthase)

82 c receptors for the molecular recognition of neuron specific enolase (NSE) biomarker.

83 rs progastrin releasing peptide (ProGRP) and neuron specific enolase (NSE) is presented, which involv

84 Serum neuron specific enolase (NSE) measurements, brain imagin

85 Double-labeled immunostaining for MCP-1 and neuron specific enolase (NSE) or glial fibrillary acidic

86 iated virus (rAAV) vectors incorporating the neuron specific enolase (NSE) promoter and either a rat

87 ibitor, noggin, or BMP4 under control of the neuron specific enolase (NSE) promoter.

88 cularly imprinted electrochemical sensor for neuron specific enolase (NSE) was developed by electroch

89 S-100b, neuron specific enolase (NSE), and tau protein were assa

90 y selected and cysteine modified epitopes of neuron specific enolase (NSE), as-synthesized gold nanop

91 lpropyl)imidazolium bromine ionic liquid and neuron specific enolase (NSE).

92 ve for A2B5, CNPase, neurofilament (NF), and neuron specific enolase (NSE).

93 s or astrocytes in transgenic mice using the neuron- specific enolase (NSE) promoter or a modified gl

94 A transgene consisting of 2.8 kb of the rat neuron-specific enolase (NSE) 5' flanking region fused t

95 Serum levels of neuron-specific enolase (NSE) and neuron-enriched S100 b

96 such as neurofilament light chain (NfL) and neuron-specific enolase (NSE) are associated with poor n

97 sensor for ultrasensitive diagnosis of human neuron-specific enolase (NSE) cancer biomarkers.

98 Moreover, the neuron-specific enolase (NSE) immunohistochemistry resul

99 ection of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) in a clinical sample with

100 Neuron-specific enolase (NSE) is a biomarker for neurona

101 Neuron-specific enolase (NSE) is a widely-used biomarker

102 Secondary outcomes were mortality and neuron-specific enolase (NSE) levels on days 1 and 3.

103 Human neuron-specific enolase (NSE) or isozyme gamma has been

104 We have found that antibodies to neuron-specific enolase (NSE) preferentially label a sub

105 (rAAV) vector, pTR-BDNFmyc, incorporated the neuron-specific enolase (NSE) promoter and the internal

106 that overexpresses BMP4 under control of the neuron-specific enolase (NSE) promoter develops a FOP-li

107 was placed under the control of 1.8-kilobase neuron-specific enolase (NSE) promoter for this purpose.

108 anscription factor, under the control of the neuron-specific enolase (NSE) promoter show both markedl

109 apoE isoforms on the brain, we have used the neuron-specific enolase (NSE) promoter to express human

110 d that overexpress BMP4 under control of the neuron-specific enolase (NSE) promoter.

111 Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if e

112 tentials, quantified pupillometry, and serum neuron-specific enolase (NSE) were retrieved.

113 rphology and expressed an increased level of neuron-specific enolase (NSE), a classical marker of neu

114 cy, is associated with increased circulating neuron-specific enolase (NSE), a marker of brain damage,

115 has been successfully used for detection of neuron-specific enolase (NSE), a traumatic brain injury

116 -6, IL-8, and IL-18), TBI biomarkers [S100B, Neuron-Specific Enolase (NSE), and epinephrine].

117 ks were analyzed for the neuromarkers S100B, neuron-specific enolase (NSE), and glial fibrillary acid

118 h the reliability of neurologic examination, neuron-specific enolase (NSE), and median nerve somatose

119 mmunohistochemistry using rabbit antisera to neuron-specific enolase (NSE), tyrosine hydroxylase (TH)

120 cal staining showed that these cells contain neuron-specific enolase (NSE), tyrosine hydroxylase (TH)

121 Serotonin, neuron-specific enolase (NSE), ubiquitin carboxyl termin

122 c mice expressing apoE3 or apoE4 in neurons [neuron-specific enolase (NSE)-apoE] or astrocytes [glial

123 ons, as demonstrated by co-localization with neuron-specific enolase (NSE)-IR, but is especially prom

124 ical (PEC) immunosensor for the detection of neuron-specific enolase (NSE).

125 Tau had higher accuracy than serum neuron-specific enolase (NSE; the area under the receive

126 llin 2 [ADM2], histamine receptor H1 [HRH1], neuron-specific enolase [NSE] [ENO2], neuronal protein g

127 glial fibrillary acidic protein [GFAP], and neuron-specific enolase [NSE]), and information about in

128 b3J/db3J and db/db mice bearing a transgene (neuron-specific enolase [NSE]-Rb) expressing the B isofo

129 (a total of 137 lactate dehydrogenase and 77 neuron-specific enolase observations), the statistical f

130 equal to 25%, and a baseline plasma level of neuron-specific enolase of greater than 15 ng/mL indepen

131 electroencephalography reactivity, and serum neuron-specific enolase offers the best outcome predicti

132 inal cultures, subsequently characterized by neuron-specific enolase or glial fibrillary acidic prote

133 /chemokine (C-C motif) ligand 2 (p = 0.030), neuron-specific enolase (p = 0.006), and S100b (p = 0.01

134 tivariate analysis, markedly elevated plasma neuron-specific enolase (P = 0.016; hazard ratio, 2.9; 9

135 c activity, and expression of the NE markers neuron-specific enolase, parathyroid hormone-related pep

136 Elevated baseline chromogranin A, neuron-specific enolase, placental growth factor, and so

137 ase elevation should be actively considered: neuron-specific enolase-producing tumors, acute brain di

138 utant ICE-lacZ gene under the control of the neuron specific enolase promoter appeared neurologically

139 overexpressing human DeltaE-torsinA using a neuron specific enolase promoter.

140 g PDGF-A in neurons under the control of the neuron-specific enolase promoter (NSE-PDGF-A) resulted i

141 ying beta-galactosidase under the control of neuron-specific enolase promoter (NSE::LacZ) from the SV

142 hamster PrP from the PrP promoter (tg7), the neuron-specific enolase promoter (tgNSE), or the astrocy

143 , we expressed Fig4 under the control of the neuron-specific enolase promoter and the astrocyte-speci

144 ith a bcl-2 transgene under the control of a neuron-specific enolase promoter have increased numbers

145 ction of expressing soluble NCAM-EC from the neuron-specific enolase promoter in the developing and m

146 signaling in palate development, we used the neuron-specific enolase promoter to express the beta3 su

147 expressing heme oxygenase-1 (HO-1) using the neuron-specific enolase promoter were impaired in learni

148 xpressing the POMC gene under control of the neuron-specific enolase promoter were produced.

149 overexpress noggin under the control of the neuron-specific enolase promoter) or fewer than normal (

150 ne-regulated system under the control of the neuron-specific enolase promoter, of several lines of mi

151 d in neurons cultured from brain cortices of neuron-specific enolase promoter-driven apoE3 (NSE-apoE3

152 P) inhibitor Noggin under the control of the neuron-specific enolase promoter.

153 of transgenic mice under the control of the neuron-specific enolase promoter.

154 or apoE4 in neurons under the control of the neuron-specific enolase promoter.

155 3 or apoE4 in the brain under control of the neuron-specific enolase promoter.

156 e overexpressing CatB under the control of a neuron-specific enolase promoter.

157 drogenase 1 (Glud1) under the control of the neuron-specific enolase promoter.

158 orrelated with 1- and 4-hr postresuscitation neuron-specific enolase (r = -.86, p < .001 and r = -.87

159 Immunostaining for neuron specific enolase revealed that the cultures were

160 th with clinical and biochemical parameters (neuron-specific enolase, S-100).

161 We included studies that investigated neuron-specific enolase, S100 calcium-binding protein be

162 ient, and these markers include 14-3-3, tau, neuron-specific enolase, S100B, and alpha-synuclein.

163 We measured serum neuron-specific enolase, S100b, and myelin basic protein

164 nt protein 1/chemokine (C-C motif) ligand 2, neuron-specific enolase, S100b, intercellular adhesion m

165 A neuron-specific enolase serum concentration greater than

166 An neuron-specific enolase serum concentration less than or

167 We analyzed neuron-specific enolase serum concentrations 3 days afte

168 Neuron-specific enolase serum concentrations less than o

169 High neuron-specific enolase serum concentrations reliably pr

170 -0.52 [95% CI, -2.23 to 1.19]; P = .40), or neuron-specific enolase (SMD, -0.00 [95% CI, -1.99 to 1.

171 uantitative PLR correlated with higher serum neuron-specific enolase (Spearman r = -0.52, p < 0.0001)

172 Receiver operator curves for serum S100b and neuron-specific enolase to classify favorable versus unf

173 added value of the serum biomarkers S100 and neuron-specific enolase to clinical characteristics for

174 ir6.2 mRNA was present in neurons expressing neuron-specific enolase, tyrosine hydroxylase, neuropept

175 le outcome were 2.89 (95% CI, 1.09-7.73) for neuron-specific enolase, using a cutoff of 62.0 ng/mL, a

176 Neuron-specific enolase was an accurate predictor of neu

177 Messenger RNA levels of CREB and neuron-specific enolase were determined in total RNA by

178 osensory evoked potentials (SSEP), and serum neuron-specific enolase were performed in parallel, as p

179 tion, electroencephalography reactivity, and neuron-specific enolase yielded the best predictive perf